 Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 1 | 1 | | 2002 | 3 | 0 | 3 | | 2003 | 2 | 3 | 5 | | 2004 | 0 | 2 | 2 | | 2005 | 2 | 1 | 3 | | 2006 | 3 | 2 | 5 | | 2007 | 1 | 5 | 6 | | 2008 | 3 | 4 | 7 | | 2009 | 3 | 3 | 6 | | 2010 | 2 | 1 | 3 | | 2011 | 3 | 2 | 5 | | 2012 | 3 | 4 | 7 | | 2013 | 3 | 2 | 5 | | 2014 | 1 | 7 | 8 | | 2015 | 3 | 5 | 8 | | 2016 | 5 | 2 | 7 | | 2017 | 1 | 2 | 3 | | 2018 | 2 | 6 | 8 | | 2019 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Stone NN, Crawford ED, Skouteris VM, Arangua P, Metsinis PM, Lucia MS, La Rosa FG, Werahera PN. The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate. J Urol. 2019 08; 202(2):264-271.
-
Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist. 2019 09; 24(9):1149-e807.
-
Miller DR, Ingersoll MA, Chatterjee A, Baker B, Shrishrimal S, Kosmacek EA, Zhu Y, Cheng PW, Oberley-Deegan RE, Lin MF. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. Free Radic Biol Med. 2019 08 01; 139:24-34.
-
Kim SP, Tilburt JC, Shah ND, Yu JB, Konety B, Nguyen PL, Abouassaly R, Williams SB, Gross CP. A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. Clin Genitourin Cancer. 2019 06; 17(3):e472-e481.
-
Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
-
Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 05; 123(5):854-860.
-
Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1504-1515.
-
Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 12; 17(4):1103-1108.
-
Kim SP, Shah ND, Meropol NJ, Tilburt JC, Nguyen PL, Yu JB, Abouassaly R, Kim A, Gross CP. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Eur Urol Oncol. 2019 03; 2(2):189-195.
-
Robin TP, Maroni PD, Chin BB, La Rosa FG, Bernard B, Pugh TJ. Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification. Oncology (Williston Park). 2018 07 15; 32(7):360-3, 369, CV3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|